BNP Paribas Upgrades Novonesis to Neutral, Boosts PT
BNP Paribas on Friday upgraded Danish biotechnology company Novonesis (NSIS-B.CO) to neutral from underperform and raised its price target to 415 Danish kroner from 362 kroner. ( covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: )
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.